Elisa Agostinetto
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
Elisa Agostinetto
May 18, 2024, 08:47 |
Blog
Elisa Agostinetto: At ESMO Breast24, Hope Rugo presents results of CAPItello-291
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared a post on X/Twitter: ''At…
May 18, 2024, 04:13 |
Blog
Elisa Agostinetto: Is this a new predictive biomarker for PFS with camizestrant
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared a post on X/Twitter: ''At…
May 18, 2024, 02:04 |
Insight
Elisa Agostinetto: At ESMO Breast24 Christine Desmedt presents an analysis of germline BRCA1/2 mutation
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared on X: “At ESMO Breast24…
May 17, 2024, 15:08 |
Societies
Elisa Agostinetto: our poster exploring histologic subtypes of early breast cancers at ESMOBreast24
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared on X: "At ESMOBreast24, we…
May 8, 2024, 23:17 |
Insight
Giampaolo Bianchini: Join us at the next ESMO Virtual Plenary session!
Elisa Agostinetto, Research Physician at Institute of Jules Bordet in Brussels, shared a post by Giampaolo…
May 7, 2024, 06:28 |
Insight
Elisa Agostinetto: The long and winding road to biomarkers for immunotherapy
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared on LinkedIn: "The long and…
Apr 23, 2024, 10:13 |
Blog
Nikolina Dodlek: We had an opportunity to host the 3rd European Cancer Organisation Young Cancer Professionals group meeting, 1st for this year
Nikolina Dodlek, Head Nurse Department for Oncology at University Hospital Centre Osijek, shared on LinkedIn:…
Apr 20, 2024, 14:18 |
Blog
Elisa Agostinetto: The proportion of patients with an actionable alteration (AA) in serial cfDNA decreases with time
Elisa Agostinetto, Clinical Research Fellow at Jules Bordet Institute in Brussels, shared a post on…
Apr 15, 2024, 17:01 |
Drugs
Elisa Agostinetto: It’s likely that adjuvant Pembrolizumab has a lower impact compared to neoadjuvant Pembrolizumab
Elisa Agostinetto, Research Physician at the Institute of Jules Bordet in Brussels, posted on X/Twitter:…
Apr 3, 2024, 15:19 |
Insight
Elisa Agostinetto: A pooled analysis exploring tumor intrinsic subtypes in 3 trials on HER2+ EBC
Elisa Agostinetto, Research Physician at Institute of Jules Bordet in Brussels, posted on X/Twitter: "Out…
1
2
3
All:
30
Posts:
11 - 20
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
15 Posts You Should Not Miss From The 1st Day of ESMOGI24
Facebook
RSS Feed
Twitter
Linkedin
Youtube